Cited by 508Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsMesenchymal stem cell research

Senescent Cells in Cancer Therapy: Friends or Foes?

Open access
Wang, Boshi, Kohli, Jaskaren, Demaria, Marco·2020·Trends in Cancer

Abstract

Several cancer interventions induce DNA damage and promote senescence in cancer and nonmalignant cells. Senescent cells secrete a collection of proinflammatory factors collectively termed the senescence-associated secretory phenotype (SASP). SASP factors are able to potentiate various aspects of tumorigenesis, including proliferation, metastasis, and immunosuppression. Moreover, the accumulation and persistence of therapy-induced senescent cells can promote tissue dysfunction and the early onset of various age-related symptoms in treated cancer patients. Here, we review in detail the mechanisms by which cellular senescence contributes to cancer development and the side effects of cancer therapies. We also review how pharmacological interventions to eliminate senescent cells or inhibit SASP production can mitigate these negative effects and propose therapeutic strategies based on the age of the patient.

Integrity signals

Registry

Crossref · 10.1016/j.trecan.2020.05.004

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several SASP factors are associated with pro-tumorigenic processes, including chronic inflammation, mitogenic signalling, stemness, angiogenesis, migration and invasion, genotoxicity and immunosuppression.

    “Several SASP factors are associated with pro- tumorigenic processes, including chronic inflam mation, mitogenic signalling, stemness, angiogenesis, migration and invasion, genotoxicity and immuno sup pression 84,156 (Supplementary Table1 and Fig.2 ).”

    From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [156]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wang, B., Kohli, J., & Demaria, M.
Affiliations
University Medical Center Groningen (NL)
Corresponding author
Demaria, Marco
Venue
Trends in Cancer
Publisher
Elsevier BV
Published
2020-10
Volume
6
Issue
10
Pages
838-857
ISSN
  • 2405-8025 (ISSN-L)
  • 2405-8033
OpenAlex
W3029435888
Cited by
508
References
44
Citations by year
2026: 50 · 2025: 90 · 2024: 115 · 2023: 80 · 2022: 92 · 2021: 69 · 2020: 12
FWCI
8.08
Type
journal article
Language
en
Open access
Locations
  • Trends in cancer (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders
KWF Kankerbestrijding
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
Keywords
cellular senescence, senescence-associated secretory phenotype, cancer treatment side effects, DNA damage, carcinogenesis, metastasis, immunosuppression, tissue dysfunction, age-related symptoms, senolytics, pharmacological interventions, patient age
MeSH terms
Humans, Neoplasms, Cellular Senescence, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review